Arrow Left Home

About us

Lygature is a not-for-profit organization based in the Netherlands. It drives the development of new medical solutions for patients by managing public-private partnerships involving academia, industry and society. Every day, Lygature brings together people in many different disciplines and organizations – to pioneer solutions in medical technology and pharmacotherapy, and to serve patients worldwide.

Find out more about who we are and what we do:

The case for partnership
With the increase in life expectancy, further globalization, and demographic change, a societal need to ensure health and wellbeing is high on the agenda. > More

Vision
Developing medical solutions is becoming more and more complex as stakeholder roles change. Partners need to share resources, knowledge, and expertise. > More

Mission
Partners should be best apart, better together – with every partner at the top of its own field, and with combined expertise suited to collaboration. Lygature works to ensure successful outcomes from public-private partnerships in biomedical innovation, including complex multi-partner programs.  > More

Our approach
Lygature offers highly skilled professionals with experience in academic and industrial settings, regulatory affairs, data infrastructure, (scientific) communication, and more. They add scientific rigor, build trust, and reap the benefits of combining the fields of MedTech and Pharma. > More

Legacy
Lygature is the result of a merger between two of the world’s largest public-private partnerships in biomedical innovation: the Center for Translational Molecular Medicine (CTMM) and Top Institute Pharma (TI Pharma). > More

Governance
Details of our Board of Directors, Management Team and Scientific Advisory Board. > More

Lygature: our name explained
Lygature takes its name from the ligatures used to bring components together, in typography, music, and medicine. > More

Team
An introduction to the people who make Lygature a successful cross-sector and cross-disciplinary partner. > More

Share this page…